Initial Treatment and Cost of Care in Pulmonary Hypertension

May 1, 2018

A new study finds that the first treatment chosen to treat PAH may help mitigate the burden of all-cause cost of care.

Treatment options for PAH are evloving, yet patient prognosis remains poor. PAH also confers a heavy ecomomic burden related to cost of drugs, hospitalizations, and comorobidities. There is research that suggests initial treatment with PAH-specific medications (vs combinations of agents) may decrease healthcare utilization. Could this strategy tranlsate into reduced overall healthcare costs to treat PAH?